Elucid, a Boston-based medical imaging company, has closed a $55 million Series D financing round that it described as oversubscribed, bringing its total capital raised to date to approximately $185 million. The round, announced in early September 2026, arrives as the company tries to move its artificial-intelligence-driven cardiovascular imaging software from a niche research tool into a routine part of how hospitals screen for heart disease. Unlike many health AI companies chasing a single blockbuster device, Elucid has spent nearly a decade building two complementary products aimed at the same underlying problem: doctors often cannot tell, from a CT scan alone, which plaque in a patient’s arteries is likely to rupture and cause a heart attack.
What Plaque-IQ actually measures
Elucid’s flagship product, Plaque-IQ, has already secured FDA clearance and is built to analyze coronary and carotid computed tomography angiography scans that patients undergo for entirely different diagnostic reasons. Rather than simply flagging a blockage percentage the way conventional CT angiography software does, Plaque-IQ characterizes the composition of plaque itself, distinguishing calcified, fibrous and lipid-rich material inside the vessel wall. That distinction matters clinically because the plaques most likely to trigger a heart attack are often not the ones that narrow an artery the most; a plaque with a thin fibrous cap sitting over a lipid-rich core can rupture and cause a sudden clot even in a vessel that otherwise looks only moderately narrowed on a standard scan. By quantifying that composition automatically, Elucid’s software gives radiologists and cardiologists a risk signal that a visual read alone would likely miss.
A second product waiting on FDA review
The Series D proceeds will also support Elucid’s newer offering, BioIntegrated FFR-CT, which estimates fractional flow reserve, a measure of how much a blockage is actually restricting blood flow, directly from CT imaging rather than requiring an invasive catheter-based procedure. The company’s 510(k) submission for that tool is currently under FDA review, and executives have said the new capital is earmarked in part for the clinical evidence and regulatory work needed to bring it to market. If cleared, BioIntegrated FFR-CT would let hospitals combine anatomical plaque characterization and functional blood-flow assessment from the same non-invasive scan, potentially reducing the number of patients referred for invasive angiography purely to determine whether a blockage is serious enough to treat.
Who backed the round
The financing included participation from IAG Capital Partners and Elevage Medical Technologies, and notably added a fourth publicly traded strategic medtech investor whose identity the company has not disclosed. That pattern, in which large, established device makers quietly take equity stakes in smaller AI imaging companies rather than building competing software in-house, has become increasingly common in cardiovascular imaging over the past two years, as incumbents look to bolt on AI capabilities rather than develop them from scratch.
The bigger diagnostic backdrop
Cardiovascular disease remains the leading cause of death in the United States, and CT angiography volumes have climbed steadily as the scans become a first-line tool for evaluating chest pain in emergency departments and outpatient cardiology clinics alike. That volume has created both an opportunity and a bottleneck: radiologists are reading more coronary CT scans than ever, but plaque composition analysis by eye is time-consuming and inconsistent between readers. Automated software that can standardize that read, the argument goes, does for plaque assessment roughly what AI triage tools have already done for detecting strokes or pulmonary embolisms on other types of scans, turning a subjective, effort-intensive interpretation into a fast, repeatable measurement.
Skeptics want outcomes data, not just funding rounds
Not everyone in cardiology is convinced that plaque-composition software changes what doctors actually do for patients. Critics of AI-driven risk stratification tools note that a growing body of imaging analytics has not always translated into changed treatment decisions or better patient outcomes, and that some hospitals have been reluctant to reimburse for software-based reads on top of the scan itself. Proponents counter that Plaque-IQ’s FDA clearance and the growing strategic investor interest suggest health systems increasingly see composition-based plaque analysis as clinically actionable rather than merely descriptive, particularly for patients whose blockage severity alone would not have flagged them as high risk.
What comes next
With the new funding in hand, Elucid says it plans to accelerate commercialization of both products across additional hospital systems and to fund further clinical studies meant to demonstrate that plaque composition data changes how physicians manage patients, whether through more aggressive statin therapy, closer monitoring or earlier intervention. The FFR-CT clearance decision, expected to land sometime after this round closes, will likely determine how quickly Elucid can position itself as a single-scan alternative to more invasive cardiac workups. For an AI health sector that has been dominated by radiology triage tools built to catch acute emergencies, Elucid’s bet is that the bigger long-term market lies in chronic disease risk prediction, one CT scan at a time.
Photo: AS_Photography / PIXABAY via Pixabay
